Abstract
Systemic sclerosis (SSc), or scleroderma, is a rare, complex, systemic autoimmune disease of unknown aetiology, characterized by high morbidity and mortality often resulting from cardiopulmonary complications such as interstitial lung disease and pulmonary arterial hypertension. Despite substantial progress in unravelling the pathways involved in the pathogenesis of SSc and the increasing number of therapeutic targets tested in clinical trials, there is still no cure for this disease, although several proposed treatments might limit the involvement of specific organs, thereby slowing the natural history of the disease. A specific focus of recent research has been to address the plethora of unmet needs regarding the global management of SSc-related interstitial lung disease, including its pathogenesis, early diagnosis, risk stratification of patients, appropriate treatment regimens and monitoring of treatment response, as well as the definition of progression and predictors of progression and mortality. More refined stratification of patients on the basis of clinical features, molecular signatures, identification of subpopulations with distinct clinical trajectories and implementation of outcome measures for future clinical trials could also improve therapeutic management strategies, helping to avoid poor outcomes related to lung involvement.
Key points
-
Systemic sclerosis (SSc) is a rare systemic autoimmune disease characterized by high clinical heterogeneity, in which interstitial lung disease (ILD) is one of the main causes of morbidity and mortality.
-
Despite many advances in the understanding of pathogenetic mechanisms and clinical definition, SSc–ILD management is still associated with several unmet needs.
-
Discovery of new therapeutic targets and specific diagnostic and prognostic markers will help optimize the management of SSc–ILD.
-
Stratification of patients by clinical features and molecular signatures, identification of subpopulations with distinct clinical trajectories, and implementation of outcome measures in clinical trials can also improve SSc–ILD management.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Volkmann, E. R., Andréasson, K. & Smith, V. Systemic sclerosis. Lancet 401, 304–318 (2023).
Denton, C. P., Wells, A. U. & Coghlan, J. G. Major lung complications of systemic sclerosis. Nat. Rev. Rheumatol. 14, 511–527 (2018).
Elhai, M. et al. Mapping and predicting mortality from systemic sclerosis. Ann. Rheum. Dis. 76, 1897–1905 (2017).
Perelas, A., Silver, R. M., Arrossi, A. V. & Highland, K. B. Systemic sclerosis-associated interstitial lung disease. Lancet Respir. Med. 8, 304–320 (2020).
Giacomelli, R. et al. Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol. Int. 37, 853–863 (2017).
Wijsenbeek, M., Suzuki, A. & Maher, T. M. Interstitial lung diseases. Lancet 400, 769–786 (2022).
Cabral-Marques, O. & Riemekasten, G. Vascular hypothesis revisited: role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis. Autoimmun. Rev. 15, 690–694 (2016).
Di Benedetto, P. et al. Endothelial-to-mesenchymal transition in systemic sclerosis. Clin. Exp. Immunol. 205, 12–27 (2021).
Li, Z. & Jimenez, S. A. Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro. Arthritis Rheum. 63, 2473–2483 (2011).
Wermuth, P. J., Li, Z., Mendoza, F. A. & Jimenez, S. A. Stimulation of transforming growth factor-β1-induced endothelial-to-mesenchymal transition and tissue fibrosis by endothelin-1 (ET-1): a novel profibrotic effect of ET-1. PLoS One 11, e0161988 (2016).
Ludwicka‐Bradley, A., Silver, R. M. & Bogatkevich, G. S. Coagulation and autoimmunity in scleroderma interstitial lung disease. Semin. Arthritis Rheum. 41, 212–222 (2011).
Dowson, C., Simpson, N., Duffy, L. & O’Reilly, S. Innate immunity in systemic sclerosis. Curr. Rheumatol. Rep. 19, 2 (2017).
Ryu, C. et al. Bioactive plasma mitochondrial DNA is associated with disease progression in scleroderma-associated interstitial lung disease. Arthritis Rheumatol. 72, 1905–1915 (2020).
Reyfman, P. A. et al. Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 199, 1517–1536 (2019).
Renzoni, E. A., Poletti, V. & Mackintosh, J. A. Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia? Lancet 398, 1437–1449 (2021).
Pechkovsky, D. V. et al. Alternatively activated alveolar macrophages in pulmonary fibrosis — mediator production and intracellular signal transduction. Clin. Immunol. 137, 89–101 (2010).
Trombetta, A. C. et al. A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement. Respir. Res. 19, 186 (2018).
Valenzi, E. et al. Disparate interferon signaling and shared aberrant basaloid cells in single-cell profiling of idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease. Front. Immunol. 12, 595811 (2021).
Liossis, S. C. & Staveri, C. The role of B cells in scleroderma lung disease pathogenesis. Front. Med. 9, 936182 (2022).
Aravena, O. et al. TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients. Arthritis Res. Ther. 19, 8 (2017).
Higashioka, K. et al. Generation of a novel CD30+ B cell subset producing GM-CSF and its possible link to the pathogenesis of systemic sclerosis. Clin. Exp. Immunol. 201, 233–243 (2020).
François, A. et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res. Ther. 15, R168 (2013).
Dumoitier, N. et al. Scleroderma peripheral B lymphocytes secrete Interleukin-6 and transforming growth factor β and activate fibroblasts. Arthritis Rheumatol. 69, 1078–1089 (2017).
Fava, A. et al. Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma. Arthritis Res. Ther. 18, 99 (2016).
Luzina, I. G. et al. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum. 48, 2262–2274 (2003).
Ramahi, A., Altorok, N. & Kahaleh, B. Epigenetics and systemic sclerosis: an answer to disease onset and evolution? Eur. J. Rheumatol. 7, S147–S156 (2020).
Orvain, C., Assassi, S., Avouac, J. & Allanore, Y. Systemic sclerosis pathogenesis: contribution of recent advances in genetics. Curr. Opin. Rheumatol. 32, 505–514 (2020).
Feghali-Bostwick, C., Medsger, T. A. Jr & Wright, T. M. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 48, 1956–1963 (2003).
Ramos, P. S. et al. Integrative analysis of DNA methylation in discordant twins unveils distinct architectures of systemic sclerosis subsets. Clin. Epigenetics. 11, 58 (2019).
Rubio-Rivas, M., Moreno, R. & Corbella, X. Occupational and environmental scleroderma. Systematic review and meta-analysis. Clin. Rheumatol. 36, 569–582 (2017).
Boesch, M. et al. Transcriptomic profiling reveals disease-specific characteristics of epithelial cells in idiopathic pulmonary fibrosis. Respir. Res. 21, 165 (2020).
DeMizio, D. J. & Bernstein, E. J. Detection and classification of systemic sclerosis-related interstitial lung disease: a review. Curr. Opin. Rheumatol. 31, 553–560 (2019).
van den Hoogen, F. et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 65, 2737–2747 (2013).
Hoffmann-Vold, A. M. et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am. J. Respir. Crit. Care Med. 200, 1258–1266 (2019).
Hoffmann-Vold, A. M. et al. The need for a holistic approach for SSc-ILD — achievements and ambiguity in a devastating disease. Respir. Res. 21, 197 (2020).
Bernstein, E. J. et al. Performance characteristics of pulmonary function tests for the detection of interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 72, 1892–1896 (2020).
Frauenfelder, T. et al. Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: a prospective study. Ann. Rheum. Dis. 73, 2069–2073 (2014).
Kowal-Bielecka, O. et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann. Rheum. Dis. 76, 1327–1339 (2017).
Hoffmann-Vold, A. M. et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol. 2, e71–e83 (2020).
Rahaghi, F. F. et al. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. Respir. Res. 24, 6 (2023).
Bernstein, E. J. et al. Computed tomography of the chest to screen for interstitial lung disease in patients with systemic sclerosis at expert scleroderma centers in the United States. ACR Open Rheumatol. 4, 596–602 (2022).
Roofeh, D., Jaafar, S., Vummidi, D. & Khanna, D. Management of systemic sclerosis associated interstitial lung disease. Curr. Opin. Rheumatol. 31, 241–249 (2019).
Khanna, D. et al. Connective tissue disease-associated interstitial lung diseases (CTD-ILD): report from OMERACT CTD-ILD working group. J. Rheumatol. 42, 2168–2171 (2015).
Bernstein, E. J., Khanna, D. & Lederer, D. J. Screening high-resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: a global survey of rheumatologists. Arthritis Rheumatol. 70, 971–972 (2018).
Bruni, C. et al. Developing a screening tool for the detection of interstitial lung disease in systemic sclerosis: the ILD-RISC risk score. Arthritis Rheumatol. 74, 1526 (2022).
Gutierrez, M. et al. Ultrasound in the assessment of interstitial lung disease in systemic sclerosis: a systematic literature review by the OMERACT Ultrasound Group. J. Rheumatol. 47, 991–1000 (2019).
Hassan, R. I. et al. Lung ultrasound as a screening method for interstitial lung disease in patients with systemic sclerosis. J. Clin. Rheumatol. 25, 304–307 (2019).
Gargani, L. et al. Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening. Rheumatology 61, SI56–SI64 (2022).
Gigante, A. et al. Lung ultrasound in systemic sclerosis: correlation with high-resolution computed tomography, pulmonary function tests and clinical variables of disease. Intern. Emerg. Med. 11, 213–217 (2016).
Makol, A. et al. Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease. Expert Rev. Clin. Immunol. 19, 613–626 (2023).
Radić, M. et al. Pulmonary ultrasonography in systemic sclerosis-induced interstitial lung disease — a systematic review and meta-analysis. Diagnostics 13, 1429 (2023).
Gomes Guerra, M. et al. The role of lung ultrasound in systemic sclerosis: a systematic review. J. Clin. Rheumatol. 29, e32–e39 (2023).
Barskova, T. et al. Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. Ann. Rheum. Dis. 72, 390–395 (2013).
Gargani, L. et al. Prognostic value of lung ultrasound B-lines in systemic sclerosis. Chest 158, 1515–1525 (2020).
Gargani, L. et al. Lung magnetic resonance imaging in systemic sclerosis: a new promising approach to evaluate pulmonary involvement and progression. Clin. Rheumatol. 40, 1903–1912 (2021).
Goh, N. S. L. et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am. J. Respir. Crit. Care Med. 177, 1248–1254 (2008).
Ferrazza, A. M. et al. Assessment of interstitial lung disease in systemic sclerosis using the quantitative CT algorithm CALIPER. Clin. Rheumatol. 39, 1537–1542 (2020).
Carvalho, A. R. S. et al. Automatic quantification of interstitial lung disease from chest computed tomography in systemic sclerosis. Front. Med. 7, 577739 (2020).
Clukers, J. et al. Interstitial lung disease in systemic sclerosis quantification of disease classification and progression with high-resolution computed tomography: an observational study. J. Scleroderma Relat. Disord. 6, 154–164 (2021).
Distler, O. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 380, 2518–2528 (2019).
Denton, C. P. et al. Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial. Rheumatology 62, 1870–1876 (2023).
Hoffmann-Vold, A. M. et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann. Rheum. Dis. 80, 219–227 (2021).
Raghu, G. et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 205, e18–e47 (2022).
Winstone, T. A. et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 146, 422–436 (2014).
Assassi, S. et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res. Ther. 12, R166 (2010).
Plastiras, S. C. et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 55, 598–602 (2006).
Volkmann, E. R. et al. Association of symptoms of gastroesophageal reflux, esophageal dilation, and progression of systemic sclerosis-related interstitial lung disease. Arthritis Care Res. 75, 1690–1697 (2023).
Man, A. et al. Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling. Rheumatology 54, 1464–1471 (2015).
Volkmann, E. R. et al. Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial. Rheumatology 61, 4397–4408 (2022).
Khanna, D. et al. Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice. Arthritis Rheumatol. 74, 13–27 (2022).
Hoa, S., Bernatsky, S., Steele, R. J., Baron, M. & Hudson, M. Canadian Scleroderma Research Group. Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis. Rheumatology 59, 1108–1117 (2020).
Hoa, S. et al. Association between immunosuppressive therapy and incident risk of interstitial lung disease in systemic sclerosis. Chest 160, 2158–2162 (2021).
Hoa, S., Baron, M. & Hudson, M. Screening and management of subclinical interstitial lung disease in systemic sclerosis: an international survey. Rheumatology 61, 3401–3407 (2022).
Roofeh, D. et al. Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 73, 1301–1310 (2021).
Al-Sheikh, H., Ahmad, Z. & Johnson, S. R. Ethnic variations in systemic sclerosis disease manifestations, internal organ involvement, and mortality. J. Rheumatol. 46, 1103–1108 (2019).
Lescoat, A. et al. Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. Rheumatology 62, 2178–2188 (2023).
Giacomelli, R. et al. Guidelines for biomarkers in autoimmune rheumatic diseases — evidence based analysis. Autoimmun. Rev. 18, 93–106 (2019).
Cole, A. & Denton, C. P. Biomarkers in systemic sclerosis associated interstitial lung disease (SSc-ILD). Curr. Treat. Options Rheum. 8, 152–170 (2022).
Distler, O. et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur. Respir. J. 55, 1902026 (2020).
Nihtyanova, S. I. et al. Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis Rheumatol. 72, 465–476 (2020).
Ishikawa, N., Hattori, N., Yokoyama, A. & Kohno, N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir. Investig. 50, 3–13 (2012).
Tashkin, D. P. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354, 2655–2666 (2006).
Tashkin, D. P. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS 2): a randomised controlled, double-blind, parallel group trial. Lancet Respir. Med. 4, 708–719 (2016).
Goldin, J. G. et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II. Ann. Am. Thorac. Soc. 15, 1286–1295 (2018).
Volkmann, E. R. et al. Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of Scleroderma Lung Study II. ACR Open Rheumatol. 2, 362–370 (2020).
Hoyles, R. K. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54, 3962–3970 (2006).
Khanna, D. et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann. Rheum. Dis. 77, 212–220 (2018).
Maher, T. M. et al. RECITAL Investigators. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir. Med. 11, 45–54 (2023).
Borrirukwisitsak, S., Tantayakom, P. & Katchamart, W. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis. Clin. Rheumatol. 40, 2779–2789 (2021).
Acharya, N. et al. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease— a randomised controlled trial. Rheumatol. Int. 40, 703–710 (2020).
Khanna, D. et al. Combination therapy of mycophenolate mofetil and pirfenidone vs. mycophenolate alone: results from the Scleroderma Lung Study III [abstract]. Arthritis Rheumatol. 74, 1045–1047 (2022).
Burt, R. K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378, 498–506 (2011).
van Laar, J. M. et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311, 2490–2498 (2014).
Sullivan, K. M. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N. Engl. J. Med. 378, 35–47 (2018).
Crespo, M. M. et al. Lung transplantation in patients with scleroderma compared with pulmonary fibrosis: short and long-term outcomes in a single institution. Ann. Am. Thorac. Soc. 13, 784–792 (2016).
Volkmann, E. R. Natural history of systemic sclerosis-related interstitial lung disease: how to identify a progressive fibrosing phenotype. J. Scleroderma Relat. Disord. 5, 31–40 (2020).
Campochiaro, C. et al. Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review. Ther. Adv. Musculoskelet. Dis. 14, 1759720X221116408 (2022).
Allanore, Y. et al. SENSCIS-ON trial investigators. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. Ann. Rheum. Dis. 81, 1722–1729 (2022).
Volkmann, E. R. et al. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res. Ther. 18, 305 (2016).
Assassi, S. et al. Predictive significance of serum interferon-inducible protein score for response to treatment in systemic sclerosis-related interstitial lung disease. Arthritis Rheumatol. 73, 1005–1013 (2021).
Assassi, S. et al. Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease. Ann. Rheum. Dis. 81, 854–860 (2022).
Wu, W. et al. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann. Rheum. Dis. 78, 648–656 (2019).
George, P. M. et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir. Med. 8, 925–934 (2020).
Goh, N. S. et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 69, 1670–1678 (2017).
Nagy, T. et al. Clinical predictors of lung-function decline in systemic-sclerosis-associated interstitial lung disease patients with normal spirometry. Biomedicines 10, 2129 (2022).
Jandali, B. et al. The effect of anti-Scl-70 antibody determination method on its predictive significance for interstitial lung disease progression in systemic sclerosis. ACR Open Rheumatol. 4, 345–351 (2022).
Assassi, S. et al. GENISOS Study Group. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res. Ther. 12, R166 (2010).
Wu, W. et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann. Rheum. Dis. 77, 1326–1332 (2018).
Bonella, F. et al. The Gender-Age-Physiology (GAP) index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD). Eur. Resp. J. 56, 801 (2020).
Ledoult, E. et al. 18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. Arthritis Res. Ther. 23, 76 (2021).
Peelen, D. M. et al. The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. Rheumatology 59, 1407–1415 (2020).
Hoffmann-Vold, A. M. et al. EUSTAR collaborators. Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from European scleroderma trials and research. Chest 163, 586–598 (2023).
Volkmann, E. R. et al. Development of a composite outcome measure for systemic sclerosis related interstitial lung disease. Rheumatology 5, 154 (2015).
Becker, M. O. et al. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire. Ann. Rheum. Dis. 81, 507–515 (2022).
Penke, L. R. K., Speth, J., Wettlaufer, S., Draijer, C. & Peters-Golden, M. Bortezomib inhibits lung fibrosis and fibroblast activation without proteasome inhibition. Am. J. Respir. Cell Mol. Biol. 66, 23–37 (2022).
Mutlu, G. M. et al. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β1 signalling. Thorax 67, 139–146 (2012).
Bellamri, N. et al. Effects of ruxolitinib on fibrosis in preclinical models of systemic sclerosis. Int. Immunopharmacol. 116, 109723 (2023).
Kolb, M., Crestani, B. & Maher, T. M. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. Eur. Respir. Rev. 32, 220206 (2023).
Gordon, J. K. et al. Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheumatol. 70, 308–316 (2018).
Brkic, Z. et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann. Rheum. Dis. 75, 1567–1573 (2016).
Kafaja, S. et al. pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis. JCI Insight 3, e98380 (2018).
van Bon, L. et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N. Engl. J. Med. 370, 433–443 (2014).
Ross, R. L. et al. Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma. Ann. Rheum. Dis. 80, 920–929 (2021).
West, A. P. & Shadel, G. S. Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat. Rev. Immunol. 17, 363–375 (2017).
Wu, M. & Assassi, S. Dysregulation of type 1 interferon signaling in systemic sclerosis: a promising therapeutic target? Curr. Treat. Opt. Rheumatol. 7, 349–360 (2021).
Goldberg, A. et al. Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res. Ther. 16, R57 (2014).
Goh, N. S. et al. Increased epithelial permeability in pulmonary fibrosis in relation to disease progression. Eur. Respir. J. 38, 184–190 (2011).
Bennett, D. et al. Elevated level of galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis. Respir. Physiol. Neurobiol. 273, 103323 (2020).
Galecto. Galecto Announces Topline Results from Phase 2b GALACTIC-1 trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis https://ir.galecto.com/news-releases/news-release-details/galecto-announces-topline-results-phase-2b-galactic-1-trial (2023).
Bergmann, C. et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann. Rheum. Dis. 82, 1117–1120 (2023).
Author information
Authors and Affiliations
Contributions
All authors researched data for the article. All authors contributed substantially to the discussion of content. V.L., F.D.G., R.G. and F.C. wrote the article. V.L., F.D.G., R.G. and F.C. reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Rheumatology thanks Masataka Kuwana, Elizabeth Volkmann and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Liakouli, V., Ciancio, A., Del Galdo, F. et al. Systemic sclerosis interstitial lung disease: unmet needs and potential solutions. Nat Rev Rheumatol 20, 21–32 (2024). https://doi.org/10.1038/s41584-023-01044-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-023-01044-x
This article is cited by
-
Use of artificial intelligence algorithms to analyse systemic sclerosis-interstitial lung disease imaging features
Rheumatology International (2024)
-
Managing Symptoms of Systemic Sclerosis for the Allergist-Immunologist
Current Allergy and Asthma Reports (2024)